High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours

@article{Hofman2012HighMI,
  title={High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours},
  author={Michael S. Hofman and Grace Kong and Oliver C. Neels and Peter Eu and Emily Hong and Rodney J. Hicks},
  journal={Journal of Medical Imaging and Radiation Oncology},
  year={2012},
  volume={56}
}
  • M. HofmanG. Kong R. Hicks
  • Published 1 February 2012
  • Medicine, Biology
  • Journal of Medical Imaging and Radiation Oncology
INTRODUCTION Ga-68 DOTATATE (Ga-octreotate, GaTate) positron emission tomography (PET)/CT has multiple advantages compared with conventional and In-111 octreotide imaging for neuroendocrine tumours and other somatostatin-receptor expressing tumours. [] Key MethodMETHODS Fifty-nine GaTate PET/CT studies were performed over an 18-month period (52 proven or suspected gastro-entero-pancreatic or bronchial neuroendocrine tumours and seven neural crest/mesenchymal tumours).

Prospective evaluation of 68Ga‐DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers

The 68Ga‐labelled somatostatin analogues (68Ga‐DOTA‐SSAs) is becoming popular as an important diagnostic tool in neuroendocrine tumours as evidenced by a growing number of reports detailing

Impact of initial imaging with gallium‐68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors

Somatostatin analog functional imaging with gallium‐68 (Ga‐68) dotatate positron emission tomography/computed tomography (PET/CT) has demonstrated superiority in lesion detection in patients with

The value of 68Gallium‐DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series

68Gallium‐DOTATATE (68Ga‐DOTATATE) is a somatostatin analog used as a PET tracer to successfully identify neuroendocrine tumors (NETs). Due to the rarity of sinonasal NETs, there are few

68Ga‐somatostatin analogue PET‐CT: Analysis of costs and benefits in a public hospital setting

This study sought to undertake cost analysis of the two modalities in a public hospital setting and to compare them with regard to patient factors such as imaging time and radiation dose.

Ga‐68 octreotate PET/CT and Tc‐99m heat‐denatured red blood cell SPECT/CT imaging of an intrapancreatic accessory spleen

The case of a 26‐year‐old woman with an incidentally diagnosed pancreatic lesion confirmed to be an intrapancreatic accessory spleen on Tc‐99m heat‐denatured red blood cell single photon emission computed tomography/CT is presented.

The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature.

Neuroendocrine tumors (NETs) are rare group of neoplasms arising from nervous and endocrine systems. Somatostatin analogue imaging is a functional imaging modality of choice for evaluating the NETs.

Multifocal Small Bowel Carcinoid: Evaluation by 68Ga-DOTATATE PET.

Given the increased sensitivity of Ga-DOTATATE PET/CT compared with CT and In-octreotide scintigraphy, it is expected multifocal carcinoid to become increasingly recognized.

68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit.

The case of a 60-year-old man who underwent 68Ga-DOTATATE PET/CT, demonstrating an avid invasive pituitary macroadenoma, was described, demonstrating a potential treatment for challenging cases utilizing the principles of theranostics.

The impact of Ga-68 DOTATATE PET/CT imaging on management of patients with paragangliomas

Ga-68 DOTATATE PET/CT findings led to a change in the scheduled treatment plan in 90.9% of patients with suspected recurrence and the most frequent change consisted in initiation of PRRT due to disease recurrence or progression or detection of multiple metastases.
...

References

SHOWING 1-10 OF 27 REFERENCES

SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours

The impact of sequentially performed single‐photon emission computed tomography (SPECT)/CT fusion on SRS study interpretation and clinical management of neuroendocrine tumours is evaluated.

Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT

The data indicate that 68Ga-DOTA-NOC PET/CT is highly superior to 111In-OctreoScan (39% detection rate for CUP according to the literature) and can play a major role in the management of patients with patients with CUP-NET.

Clinical utility of hybrid SPECT-CT in endocrine neoplasia.

SPECT-CT provides improved specificity and diagnostic confidence helping to guide conventional management and assess suitability for targeted radionuclide therapy.

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

68Ga-DOTA-TOC PET shows a significantly higher detection rate compared with conventional somatostatin receptor scintigraphy and diagnostic CT with clinical impact in a considerable number of patients and showed higher diagnostic efficacy compared with SPECT.

The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy

In patients with negative or equivocal 111In-DTPA-octreotide findings, 68Ga-DOTATATE PET identifies additional lesions and may alter management in most cases.

Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy

Somatostatin receptor scintigraphy is an accurate imaging modality for the diagnosis of neuroendocrine tumor. Because detection of distant metastases has a major impact on treatment, early diagnosis

Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours

68Ga-DOTATOC PET is superior to 111In-DTPAOC SPECT in the detection of NET manifestations in the lung and skeleton and similar for the detection in the liver and brain and is advantageous in guiding the clinical management.

Gallium-68 PET: a new frontier in receptor cancer imaging.

The clinical and research applications of PET radio-tracers for evaluating NET, in particular gallium-68-DOTA compounds are discussed, which have significantly improved the quality of imaging NET through improved resolution of PET and higher affinity of the new generation of peptides to SSTR.

Endocrine Neoplasm Scintigraphy: Added Value of Fusing SPECT/CT Images Compared With Traditional Side-by-Side Analysis

CT correlation can be helpful in interpreting endocrine neoplasm SPECT imaging and should be performed routinely because it potentially influences clinical decision-making and patient management.

Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors.

  • M. PerriP. Erba G. Mariani
  • Medicine
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
  • 2008
ROC analysis confirmed that Octreo-SPECT/CT allows more accurate detection and localization of NETs than simple Octreospecific SPECT, with major benefits for lesions located in the abdomen.